Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Nurix Therapeutics's EPS for the twelve months ending Aug 31, 2026 was $2.31. For fiscal 2025 it was -$3.05. The highest annual figure on record is -$2.65 in fiscal 2023.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -$3.05 | – |
| FY2024 | Nov 30, 2024 | -$2.88 | – |
| FY2023 | Nov 30, 2023 | -$2.65 | – |
| FY2022 | Nov 30, 2022 | -$3.71 | – |
| FY2021 | Nov 30, 2021 | -$2.73 | – |
| FY2020 | Nov 30, 2020 | -$2.76 | – |
| FY2019 | Nov 30, 2019 | -$6.59 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $4.73 | – |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -$0.81 | – |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -$0.79 | – |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$0.82 | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -$1.03 | – |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -$0.52 | – |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -$0.67 | – |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$0.75 | – |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -$0.67 | – |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -$0.71 | – |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -$0.76 | – |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -$0.77 | – |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -$0.68 | – |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -$0.45 | – |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -$0.75 | – |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -$0.87 | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -$0.90 | – |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -$1.01 | – |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -$0.95 | – |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$0.85 | – |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -$0.65 | – |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -$0.60 | – |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | -$0.63 | – |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -$0.51 | – |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -$1.09 | – |
| Q2 FY2020CQ2 2020 | May 31, 2020 | $0.00 | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | -$3.50 | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -$3.55 | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | -$0.66 | – |
| Q2 FY2019CQ2 2019 | May 31, 2019 | -$0.89 | – |
| Q1 FY2019CQ1 2019 | Feb 28, 2019 | -$0.84 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?